Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection ...

Fintel reports that on June 6, 2025, Goldman Sachs initiated coverage of Teva Pharmaceutical Industries Limited - Depositary ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced today that its investigational drug TEV-53408 has received Fast ...

Teva Pharmaceutical Industries (TEVA) announced the pricing and early acceptance results of its previously announced tender offers to buy for cash the outstanding notes.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has unveiled new data at the 2025 Psych Congress Elevate, highlighting ...

A new study from Teva Pharmaceutical Industries Limited (NYSE:TEVA) has uncovered alarming gaps in the diagnosis and ...

Teva Pharmaceutical (TEVA) stock, Amneal Pharma (AMRX) stock receive Buy ratings and Viatris (VTRS) stock receives a Neutral rating at Goldman Sachs. Read more here.

Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's ...

Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, ...

Teva Pharmaceutical Industries Ltd. announced early results for its tender offers regarding multiple series of senior notes to proactively manage its debt capital structure and extend maturity ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has unveiled new data at the 2025 Psych Congress Elevate, highlighting significant advances in schizophrenia treatment. Real-world studies show ...

Fast Track designation granted for investigational TEV-53408, an anti-IL-15 antibodyDesignation underscores the potential of TEV-53408, currently undergoing a Phase 2a study for the treatment of celia ...